CAMP4 Therapeutics closes $100m round to advance lead regRNA programmes

Biotechnology company CAMP4 Therapeutics has closed a $100m Series B round to progress its lead regRNA programmes and speed up the expansion of its regRNA Actuating Platform.

Related Keywords

James Boylan ,Andreessen Horowitz ,Josh Mandel Brehm ,Kraft Group ,Enavate Sciences ,Patient Square ,Polaris Partners ,Northpond Ventures ,Dark Side ,